Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference123 articles.
1. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy;Ahn;Lung Cancer,2013
2. Hepatocellular carcinoma with spontaneous regression: report of the rare case;Arakawa;Hepatogastroenterology,2008
3. Human melanoma cell lines established from metastases of a patient with a completely regressed primary site;Avinoach;Cancer,1992
4. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study;Barbare;Eur. J. Cancer,2009
5. Phase III. trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J. Clin. Oncol.,2009
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Control Groups in RCTs Supporting Approval of Drugs for Systemic Rheumatic Diseases, 2012-2022;JAMA Network Open;2023-11-22
2. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations;JNCI: Journal of the National Cancer Institute;2023-10-12
3. Objective response rate of placebo in randomized controlled trials of anticancer medicines;eClinicalMedicine;2023-01
4. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021;Journal of Clinical Oncology;2022-12-10
5. A case of lymph node-positive esophageal squamous cell carcinoma with spontaneous regression of the primary lesion;Progress of Digestive Endoscopy;2022-12-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3